Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.36 |
| ▸ | CTSS | P25774 | 5/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.30 |
| ▸ | ARG2 | P78540 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18614254 | 0.84 | CTSS (0.36) | CTSKCTSSDGAT1MEN1GAA | |
| SCHEMBL18614257 | 0.84 | CTSS (0.36) | CTSKCTSSDGAT1MEN1GAA | |
| SCHEMBL4911367 | 0.83 | DGAT1 (0.32) | CTSKCTSSDGAT1CTSLCTSB | |
| SCHEMBL4939145 | 0.83 | DGAT1 (0.40) | CTSKCTSSDGAT1CTSLCTSB | |
| SCHEMBL28195825 | 0.83 | DGAT1 (0.40) | CTSKCTSSDGAT1CTSLCTSB | |
| SCHEMBL9116850 | 0.83 | DGAT1 (0.40) | CTSKCTSSDGAT1CTSLCTSB | |
| SCHEMBL27708714 | 0.82 | CTSS (0.36) | CTSKCTSSDGAT1MEN1GAA | |
| SCHEMBL27718253 | 0.82 | CTSS (0.36) | CTSKCTSSDGAT1MEN1GAA | |
| SCHEMBL27881348 | 0.81 | TAS1R3 (0.32) | — | |
| SCHEMBL4909430 | 0.81 | DGAT1 (0.32) | DGAT1MEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029567-B2 | Hypoglycemic compounds | CADILA PHARMACEUTICALS LIMITED (IN) | 2015-05-12 | — | — | US | disclosed |
| EP-2769978-A1 | saxagliptin derivatives | Cadila Pharmaceuticals Limited (IN) | 2014-08-27 | — | — | EP | disclosed |
| US-20130150578-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | CADILA PHARMACEUTICALS LIMITED (IN) | 2013-06-13 | — | — | US | disclosed |
| CN-101133060-B | Enzyme inhibitors | CHROMA THERAPEUTICS LTD | 2013-06-05 | — | — | CN | disclosed |
| EP-2555617-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | Cadila Pharmaceuticals Limited (IN) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011125011-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | CADILA PHARMACEUTICALS LIMITED (IN) | 2011-10-13 | — | — | WO | disclosed |
| CN-101133060-A | Enzyme inhibitors | CHROMA THERAPEUTICS LTD (GB) | 2008-02-27 | — | — | CN | disclosed |
| EP-0932606-B1 | INHIBITORS OF PRENYL TRANSFERASES | SOD CONSEILS RECH APPLIC (FR) | 2007-12-12 | — | — | EP | disclosed |
| EP-0932606-A4 | INHIBITORS OF PRENYL TRANSFERASES | BIOMEASURE INC (US) | 2000-01-19 | — | — | EP | disclosed |
| EP-0932606-A1 | INHIBITORS OF PRENYL TRANSFERASES | Biomeasure Incorporated (US) | 1999-08-04 | — | — | EP | disclosed |
| US-5773455-A | Inhibitors of prenyl transferases | BIOMEASURE, INCORPORATED (US) | 1998-06-30 | — | — | US | disclosed |
| WO-1998000409-A1 | INHIBITORS OF PRENYL TRANSFERASES | BIOMEASURE INCORPORATED (US) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150578-A1 | NOVEL HYPOGLYCEMIC COMPOUNDS | GLP1R, GPR119, IAPP | CTSK 3616/4885CTSS 3596/4885DGAT1 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.